

### **Unstable Intertrochanteric Fractures: Is the Best Plate a Nail?**

*Adam Tucker, MBBS<sup>1</sup>; Kevin J. Donnelly, MBBS<sup>2</sup>; Sinead McDonald<sup>2</sup>; Andrew Foster<sup>3</sup>*

<sup>1</sup>*Musgrave Park Hospital, Belfast, Northern Ireland, UNITED KINGDOM*

<sup>2</sup>*Royal Victoria Hospital, Belfast, Northern Ireland, UNITED KINGDOM*

<sup>3</sup>*Altnagelwin Area Hospital, Londonderry, Northern Ireland, UNITED KINGDOM*

**Purpose:** The management of Intertrochanteric hip fracture remains contentious. We aimed to determine if either sliding hip screws or cephalomedullary nails have superior outcomes for unstable intertrochanteric hip fractures.

**Methods:** We prospectively reviewed all unstable intertrochanteric hip fractures (AO31A2.2 to AO31A3.3) from January 2001 to December 2015 inclusive. Patient demographics, surgical details, functional scores, and 1-year mortality were assessed for 3 distinct operative procedures: sliding hip screw (SHS), SHS with trochanteric stabilization plate (SHS + TSP), and cephalomedullary nails (CMN). The data were statistically analyzed and  $P < 0.05$  considered significant.

**Results:** We identified 3451 patients of whom 3230 had full data sets available for analysis. The mean age of  $80 \pm 12$  years. The mean ages by implant were SHS  $80.5 \pm 11.6$ , SHS + TSP  $80.5 \pm 11.9$ , and CMN  $79.0 \pm 13.3$ , with a significant difference noted between SHS and CMN only ( $P = 0.016$ ). A female preponderance of 3:1 was noted. Frequency of A2.2 and A2.3 fracture subtypes increased ( $r = 0.377$  and  $r = 0.548$ , both  $P < 0.001$ ), while a nonsignificant increasing trend in A3 subgroup ( $r = 0.068$ ,  $P = 0.423$ ) was observed. Modal ASA (American Society of Anesthesiologists) grade was 3, with no difference in ASA grades between groups ( $P = 0.138$ ). SHS procedures reduced ( $r = -0.903$ ), with a concomitant increase in SHS with TSP ( $r = 0.777$ ) and CMNs ( $r = 0.864$ ). Baseline functional scores were similar. No difference was seen at 12 months postoperatively ( $P = 0.179$ ). All implants displayed functional deterioration from baseline ( $P < 0.0001$ ). The SHS + TSP group had the longest inpatient stay ( $18.1 \pm 14.3$ ), versus SHS  $12.5 \pm 9.8$  and CMN  $12.6 \pm 9.1$  ( $P < 0.001$ ). Revision rates were SHS 4.04%, SHS + TSP 2.53%, and CMN 2.34%, respectively ( $P = 0.239$ ). Kaplan Meier plots for mortality at 12 months for each group was 22.6% SHS, 27.2% SHS + TSP and 18.1% CMN ( $\chi^2(2) = 9.165$ ,  $P = 0.014$ ). Subanalysis by gender demonstrated males were at an increased risk of mortality at 12 months postoperatively.

**Conclusion:** Better baseline functional scores and a younger age may influence the use of CMNs. No functional benefit is conveyed at 12 months postoperatively. Males tended to be younger, with higher 12-month mortality risk compared to females, regardless of implant. The use of a CMN for treating unstable intertrochanteric fractures of the hip is associated with equivocal length of stay and lower mortality rates compared to a SHS, with or without an additional TSP.